Drug Interaction Report

ADJUST DOSE: Coadministration of momelotinib with rosuvastatin may increase the plasma concentration and effects of rosuvastatin. The proposed mechanism is decreased rosuvastatin clearance due to momelotinib-mediated inhibition of the intestinal and hepatobiliary efflux transporter, breast cancer resistance protein (BCRP). Clinical studies have demonstrated that concomitant use of a single dose of rosuvastatin (10 mg) with multiple daily doses of momelotinib (200 mg) increased the peak plasma concentration (Cmax) and systemic exposure (AUC) by 220% and 170%, respectively.

MANAGEMENT: If used concomitantly with momelotinib, it is recommended that rosuvastatin be commenced at a dose of 5 mg daily, up to a maximum of 10 mg daily. Patients should be advised to promptly report unexplained muscle pain, tenderness, or weakness, particularly if accompanied by malaise or fever. Some authorities suggest that alternative therapeutic agents with less potential for an interaction should be considered whenever possible.